Vital Signs - Developing Microfluidics Diagnostics; Way to Medical Revolution


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on March 5, 2007, provides a strategic overview of the potential impact of microfluidics in the healthcare and life sciences areas. Additionally, an emerging company profile is provided for Cepheid, a molecular diagnostics company that develops and markets fully-integrated genetic analysis systems for the industrial, clinical, and bio-defense markets. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of February 19 - February 23, 2007.

Table of Contents

Vital Signs - Developing Microfluidics Diagnostics; Way to Medical RevolutionVital Signs: 5 March 2007This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.